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to assess, from the governmental perspective, the cost-effectiveness of using QIV 
versus TIV as an influenza vaccination for children under 17 years old. Methods: 
A Markov model was used to assess the cost and effectiveness of QIV and TIV. Cost 
data were obtained from the National Health Insurance claims data. Vaccine effi-
cacy and transition probability of different health states were based on previous 
studies. Outcomes included cases avoided, life-years gained, QALYs gained and the 
corresponding incremental cost-effectiveness ratios (ICERs). The discount rate of 
cost and effectiveness was set at 3.5% and the time horizon used in the model is 100 
years. Results: The avoided influenza-associated outcomes form QIV, compared to 
TIV, and throughout the estimate lifetime were as follows: 251,512 influenza cases 
avoided, 32,355 cases with influenza complications avoided, 254,855 outpatient vis-
its avoided, 3,860 inpatients receiving treatment for complications avoided and 717 
deaths avoided. The ICER of this alternative, compared with TIV, was US$44,231.3 per 
QALY gained. When the herd effect was taken into consideration, the ICER dropped 
to US$30,947.85 per QALY gained. ConClusions: From the governmental perspec-
tive, the QIV of seasonal influenza is associated with favorable cost-effectiveness 
ratios in children under 17 years.
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objeCtives: The purpose of this analysis was to quantify the cost-effectiveness 
of recombinant follitropin alfa (r-hFSH) and highly purified urinary follicle stimu-
lating hormone (uFSH-HP) in the in-vitro fertilization (IVF) process. Methods: 
An Excel-based model estimated the drug cost per pregnancy and drug cost per 
live birth resulting from a hypothetical cohort of 1000 women undergoing IVF in 
Germany. Model inputs were taken from peer-reviewed published literature, and 
used to estimate the number of embryos generated per IU of gonadotropin used 
for ovarian stimulation. The cohort then underwent multiple rounds of embryo 
transfers (ETs) until embryo exhaustion or pregnancy as dictated by literature val-
ues. The obtained pregnancy rates were multiplied by the percentage of live births 
achieved per pregnancy according to the 2012 German IVF Registry to generate 
the live birth analysis. The cost inputs for r-hFSH and for uFSH-HP were ex-factory 
prices provided by Merck Serono affiliates in Germany. Cost inputs were limited to 
the cost of drug, as medical costs associated with the IVF procedure were assumed 
to be equal for both r-hFSH and uFSH-HP, and would not affect the comparison. 
All of the model outputs were age-agnostic and did not take into consideration 
procedural differences amongst fertility clinics, as the referenced clinical studies 
did not provide these details. Results: Treatment with r-hFSH resulted in a cost 
per pregnancy of 173€ (235USD, 10%) (Bergh et al.) and 47€ (64USD, 2%) (Frydman 
et al.) less than treatment with uFSH-HP. The cost per live birth was 622€ (846USD, 
15%) (Bergh et al.) and 312€ (424USD, 6%) (Frydman et al.) less with r-hFSH than for 
uFSH-HP. ConClusions: r-hFSH minimises the cost per pregnancy and cost per 
live birth in Germany. The results of the model demonstrate that r-hFSH represents 
a cost-effective gonadotropin to use for IVF ovarian stimulation.
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objeCtives: The objective of this analysis is to demonstrate the economic value of 
Duratocin® in the prevention of postpartum hemorrhage from uterine atony dur-
ing active management of the third stage of labour in elective caesarean section 
delivery. Methods: We analyzed the economic value of Duratocin® (carbetocin) in 
relation to the comparators most commonly encountered in clinical practice, and 
recommended in the clinical practice guidelines of the Society of Obstetricians and 
Gynecologists of Canada. We modeled the treatment pathways as described in the 
guidelines, and also the use of uterotonics encountered in typical Canadian practice, 
i.e. as a second-line intervention. Assuming that the ultimate incidence of postpar-
tum hemorrhage is equal between all treatment strategies, we constructed cost-
minimization models in TreeAge Pro (2013), with a time horizon of 8 hours. Transition 
probabilities were derived from the literature, and costs and resource consumption 
data were obtained from hospital databases and input from health care profession-
als. Results: Duratocin® was shown to be the lowest cost treatment strategy in the 
prevention of postpartum hemorrhage in elective caesarean section delivery using 
either guidelines or typical-use treatment pathways. The total expected cost of the 
carbetocin treatment strategy under the SOGC Guidelines scenario is $22.12, vs. $24.91 
for the oxytocin strategy. In the typical use scenario the results are even clearer, 
with carbetocin providing very substantial cost-savings compared to ergonovine or 
carboprost. ConClusions: These results were robust to all sensitivity analyses in 
the case of the typical-use scenario. In the SOGC Guidelines scenario the results were 
robust to all sensitivity analyses except the dosing of ergonovine.
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objeCtives: The purpose of this analysis was to quantify the cost-effectiveness of 
recombinant follitropin alfa (r-hFSH) and highly purified human menopausal gonado-
tropin (HP-hMG) in the in-vitro fertilization (IVF) process. Methods: An Excel-based 
model was constructed to estimate the cost per oocyte retrieved, cost per embryo gen-
erated, and cost per optimal chance of live birth for r-hFSH and HP-hMG in Sweden. 
Calgary and Saskatchewan HTS protocols were found to be costly compared to 
LTS with the Calgary protocol being the most costly. The Saskatchewan protocol 
was found to be less costly than the Calgary protocol primarily due to employing 
ultrasound as the initial confirmatory diagnostic which reduces the number of 
Hysterosalpingogram (HSG) procedures conducted compared to the Calgary proto-
col. However, while HTS is more costly than LTS, it was also more effective. The costs 
saved per successful procedure lost by switching from LTS to the Saskatchewan pro-
tocol or the Calgary protocol was $3,588 and $4,789, respectively. This result suggests 
that the Saskatchewan protocol is cost effective compared to the Calgary protocol 
(i.e. within HTS comparison) because the Saskatchewan protocol saves more money 
for a unit of effectiveness lost. ConClusions: The existing evidence suggest that 
compared to LTS, HTS is more costly but also more effective. While replacing eligible 
LTS procedures with HTS will result in costs decision makers will need to determine 
whether the amount of costs outweighs the amount of effectiveness gains.
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objeCtives: To perform a complete economic evaluation of cost-effectiveness on 
the use of Floseal versus standard treatment for obstetric haemorrhage in Mexican 
patients from the Public Health Sector point of view Methods: An economic analy-
sis was designed using data base from the UMAE 23 Hospital of Gynecology and 
Obstetrics ¨Dr. Ignacio Morones Prieto¨, to compare Floseal and Control (standard 
treatment) in obstetric haemorrhage. The efficiency measure was the percentage 
of patients who avoided surgical re-intervention. Only costs from medical attention 
were used such as: haemostatic agents, hospitalization and surgery. An incremental 
cost-effectiveness analysis was performed, as well as a (deterministic and stochas-
tic) sensitivity analysis, modifying cost and effectiveness of Floseal; and reinforced 
with the statistical analysis and lineal regression to determine de influence of sev-
eral parameters on the total cost. Results: The data base prove that Floseal is a 
more cost-effectiveness option than Control; 100% of patients avoided surgical re-
intervention compared to 46.66% of the Control (p< .0001). Patients that used Floseal 
had less hospitalization time and less time in the intensive care unit with respect 
to patients with standard treatment. And, Floseal in obstetric haemorrhage had 
an average cost per patient of $137,505, while Control group was $237,470 generat-
ing savings of $99,965 per patient. The sensitivity analysis, statistical analysis and 
lineal regression analysis proved the strength of these results. ConClusions: The 
economic evaluation proved that Floseal is an cost-effectiveness and safe option 
with respect to Control, used in obstetric haemorrhage in Mexican patients, hav-
ing a lesser cost while avoiding surgical re-interventions and hospitalization days.
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objeCtives: Prenatal distribution of misoprostol has been advocated as a strategy to 
increase access to uterotonics during the third stage of labor to prevent Post Partum 
Hemorrhage (PPH). The objective of this study was to project the potential cost-effec-
tiveness of this strategy in Uganda from both governmental (payer) and societal per-
spectives. Methods: To compare prenatal misoprostol distribution to the status quo 
(no misoprostol distribution), we developed a decision model that tracked the delivery 
pathways, outcomes and cost of a pregnant woman from the prenatal period to onset 
of labor, delivery without complications or delivery with PPH, and successful treat-
ment or death. Model parameters were derived from the Uganda Demographic and 
Health Survey and the published literature, as well as expert opinion. We computed 
expected probabilities of PPH and death due to PPH, Disability Adjusted Life Years 
(DALYs) and costs. In the incremental analysis, we calculated changes in expected 
probabilities of PPH and death due to PPH, Disability Adjusted Life Years (DALYs) and 
changes in costs. We conducted univariate and probabilistic sensitivity analyses to 
examine robustness of our results. Results: In the base case analysis, the expected 
probabilities of PPH and death due to PPH were lower with prenatal misoprostol dis-
tribution (14.0% versus 16.3% and 1.4% versus 1.7% respectively). Mean DALYs were 
lower with prenatal misoprostol distribution (0.408 versus 0.511). Mean costs were 
lower with prenatal misoprostol distribution both from the governmental ($17.42 
versus $18.27) and societal ($30.02 versus $31.55) perspectives. In the incremental 
analysis, prenatal misoprostol distribution was a dominant strategy i.e. it was both 
less costly and more effective. This result was robust to univariate and probabilistic 
sensitivity analysis. ConClusions: Prenatal distribution of misoprostol is poten-
tially cost-effective in Uganda. It would potentially save lives and money and should 
be considered for national-level scale up for prevention of PPH.
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objeCtives: Influenza could cause serious consequences, especially on children. 
The WHO recommended that influenza vaccination of children is the most effective 
means. Trivalent influenza vaccine (TIV), which contains two lineages of influenza 
A virus and one lineage of influenza B virus, is now use as a first-line strategy to 
prevent influenza in Taiwan. However, when the influenza B-lineage included in the 
TIV mismatched with circulating strains, the protection of TIV would be reduced. 
Quadrivalent influenza vaccine (QIV) which includes both influenza B viruses of the 
two circulating lineages is thus proposed as an alternative. The aim of the study was 
